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Background: Transgenic animals have greatly en-
hanced our understanding of the contribution of various
structural and regulatory components to epidermal biol-
ogy. The expression of mutant versions of these compo-
nents in the epidermis of transgenic mice has generated
animal models of specific human skin diseases.
Observations. The expression of mutant keratin genes
has produced animal models of epidermolysis bullosa sim-
plex and epidermolytic hyperkeratosis and, in doing so,
has focused attention on the genetics of keratins in these
and other skin disorders. Similarly, the generation of mice
overexpressing growth factors and/or oncogenes, exclu-
sively in the epidermis, has identified the role of these
factors in normal skin and produced models of disease
states where the regulation of these factors is perturbed.
Conclusions: These models of keratin disorders and other
diseases not only enable the determination of the cause of
these disorders, but also allow evaluation of novel thera-
peutic techniques for the amelioration of these skin dis-
(Arch Dermatol. 1993;129:1430-1436)
The guiding principle be¬hind the production of ani¬mal models of human skindiseases is to perturb kera¬tinocyte function through
the unregulated expression of growth fac¬
tors or oncogenes, or by the expression of
mutant forms of structural proteins. To di¬
rect expression of these "foreign" se¬
quences to the epidermal keratinocyte, one
can use the promoter regions and regula¬
tory sequences of genes that are expressed
at high levels in these cells. These include
the genes for the keratins and other struc¬
tural proteins such as filaggrin and loric-
rin (reviewed in Rothnagel et al1). Indeed,
regulatory elements of keratins K5, K14,
K6, and K10 have been employed to drive
expression of exogenous sequences to the
epidermis and related structures.25 While
these constructs were successful in elicit¬
ing a skin phenotype, they all suffered from
various limitations including expression in
other tissues such as the esophagus, oral
cavity, or cervix. Some of these constructs
were also expressed early in utero, ie, be¬
fore day 14 of embryonic development. Ex¬
pression of exogenous sequences early in
development or in other tissues can se¬
verely compromise the viability of the ani¬
mal, often leading to death before any epi¬
dermal effects can be observed or even
extensively analyzed.5,6
To overcome these potential prob¬
lems, we used the regulatory sequences of
human keratin 1 (HK1).7"9 Human Kl is a
differentiation-specific keratin and is nor¬
mally expressed in the suprabasal layers of
the epidermis and not in basal layer kera¬
tinocytes that are undergoing cell divi¬
sion. For construction of an epidermal-
specific targeting vector, we removed the
keratin coding sequences from a 10.8-
kilobase (kb) HK1 genomic fragment and
replaced them with a "poly-linker" con¬
taining unique restriction enzyme sites. These
sites enable us to readily insert other cod¬
ing sequences into the HK1-derived tar¬
geting vector. From previous transgenic stud¬
ies, we know that the 10.8-kb fragment
expresses HK1 correctly during develop¬
ment, at day 15 of gestation, and only in
the epidermis10 (F. Y. Chung, PhD, C. K.
Cheng, MS, and J.A.R., unpublished docu¬
mentation). However, the 10.8-kb frag¬
ment also directs expression of HK1 to mi-
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totically active basal cells," which, although abnormal, is
a useful characteristic for the targeting of oncogenes and
growth factors since these proteins usually exert their in¬
fluence on cells that are capable of division. The epidermal-
specific targeting vector was first tested using the reporter
gene, ß-galactosidase (ß-gal), in both transfection assays
of cultured keratinocytes and in transgenic mice. Like the
parent fragment from which it was derived, the ß-gal con¬
struct (denoted HK1 .ß-gal) was only expressed in the epi¬
dermis, in both basal and suprabasal layers, and late in
gestation. Having established these parameters, we un¬
dertook a series of experiments to develop mouse models
of both inherited and acquired epidermal disorders.
TRANSGENIC MODELS OF DOMINANTLY
INHERITED DISORDERS OF KERATIN
The problem facing cutaneous researchers is that while
many skin disorders display similar clinical symptoms they
are genetically very heterogeneous. For example, clini¬
cally similar diseases such as the ichthyoses or epider-
molyses result from at least 15 different genotypes, re¬
spectively.12 This heterogeneity arises from the complex
integration of the various components that are required
to function together to maintain a normal epidermis. One
could envisage that the collapse of the keratin filament
network of epidermal cells, such as occurs in the skin
diseases of epidermolysis bullosa simplex (EBS) and epi-
dermolytic hyperkeratosis (EHK), could result from a de¬
fect in a number of components. These include defects in
the keratin subunits themselves, defects in the proteins
that are responsible for anchoring these filaments to the
cell periphery, or perhaps defects in the various biochemi¬
cal processes that mediate posttranslational modifications
of these components. As an example, the potential mo¬
lecular basis of EHK was variously predicted to involve
abnormalities in a number of epidermal proteins includ¬
ing keratins, fillagrin, involicrin, desmosomal compo¬
nents, or defects in lipid metabolism (Rothnagel et al13
and references listed therein). Reverse genetic studies in
transgenic animals are a powerful means to investigate
the contribution of a particular gene mutation to a given
phenotype. The first example of this type of an approach
to a skin disorder involved transgenic mice that ex¬
pressed a mutant keratin K14 gene. These mice showed
a phenotype that resembled the autosomal dominant hu¬
man skin disease, EBS.14 Similarly, transgenic mice pro¬
duced with this mutant, but driven by a keratin K10 pro¬
moter and expressed in the suprabasal cells of the epidermis,
exhibited a phenotype with some but not all the charac¬
teristics of EHK.15
We have since produced transgenic mice expressing
mutations in HK1 (HK1A2B) that more closely mimic this
disease. In general, heterozygous mice produced from these
founders exhibited subtle phenotypes at birth that were
not sustained. Homozygous mice that bear two copies of
the mutant transgene alíele showed more severe symp¬
toms and usually died within 24 to 36 hours after birth.
These symptoms were very reminiscent of the human dis¬
ease and include the appearance of hemorrhagic and non-
hemorrhagic vesicles within 24 hours of birth(Figure 1, top) that later progressed to frank erosions.
Old lesions showed an influx of inflammatory cells and
other evidence of secondary infections. Histologie exami¬
nation of skin biopsy specimens revealed cell lysis and
intraepidermal splitting in the suprabasal keratinocytes(Figure 1, bottom). Moreover, many clear cells were ob¬
served in the upper spinous layer similar to clear cells
seen in patients with EHK. Ultrastructurally, these clear
spinous cells show the same clumping of keratin fila¬
ments around the nucleus as seen in EHK. The kerato-
hyalin granules also appeared abnormal in these cells, which
is another hallmark of the human disease. It is interesting
that in those mice that survived to adulthood, the sever¬
ity of the phenotype was diminished. Juvenile and adult
mice did not exhibit blistering or suprabasal epidermal
splitting in their densely haired back skin; however, their
footpad epithelium, which lacks hair follicles, did show
cell lysis and splitting in the spinous layer and resembled
classic EHK. The fact that symptoms are more pro¬
nounced in homozygous mice suggests that a certain criti¬
cal concentration of the mutant HK1, over that of the en¬
dogenous Kl, is required to cause a disturbance of the
Figure 1. Top, Gross phenotypic morphologic appearance of a newborn
HK1A2B transgenic pup showing intact and ruptured vesicles. Bottom,
Histologie appearance of transgenic skin shows focal intraepidermal
acantholysis and clefting (magnification x 167).
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Figure 2. Top, Gross phenotypic morphologic appearance of a newborn
HK1. TGF-a transgenic pup (right) and a normal Mérmate (left). Bottom
left, Histologie appearance of transgenic skin shows hyperplasia and a lack
of hair follicles or other appendages. Compare with control skin (bottom
right) (magnification x 167).
Figure 3. Top, Typical HK1.ras tumor appearing by 10 to 12 weeks of age
often at sites of wounding by the ear tag, or areas exposed to repeated
biting or scratching. Bottom, Histotype reveals a well-differentiated
squamous papilloma, with little dysplasia and no indications of malignant
conversion or carcinoma in situ (magnification x 167).
keratin filament network. The lack of a phenotype in hairy
skin suggests that hair follicles are able to stabilize or pro¬
tect the epidermis from physical trauma. In any case, these
mice have confirmed that mutations in keratin can give
rise to skin disorders. Indeed, subsequent to these trans¬
genic studies, researchers have found mutations in the
coding region of the genes for K5 and K14 in patients
with EBS.1618 More recently, we and others have identi¬
fied mutations in highly conserved regions of both Kl
and K10 in patients with EHK.13,19,20
TRANSGENIC MODELS
OF GROWTH FACTOR DISTURBANCES
One of the phenotypic differences between EBS and EHK
is the predominance ofhyperkeratotic lesions in the latter.
Moreover, it has been shown that transforming growth fac¬
tor alpha (TGF-a) levels are increased in EHK lesions.21
Increased TGF-a levels have also been observed in other
skin disorders that are associated with abnormal regula¬
tion of growth, such as psoriasis.22 Transforming growth
factor a is a potent mitogen that is structurally related to
the epidermal growth factor (EGF) family of proteins and,
indeed, functions by binding to the EGF receptor.23 The
TGF-a is produced by keratinocytes and is more potent
than EGF in stimulating growth and cell migration24 and
may play a role in the response to wounding.25 To explore
the contribution of TGF-a to a hyperkeratotic epidermis,
we targeted TGF-a to the epidermis of transgenic animals.26
The mice expressing the construct HKl.TGF-a exhibited
a marked hyperplasia (Figure 2) that later developed into
hyperkeratosis not unlike that seen in EHK patients. This
phenotype disappeared with age in most animals but was
retained in animals with high expression levels of the trans-
gene. The reduction of the hyperplasia and accompanying
keratosis may be a consequence of the reduction in EGF
receptor levels, leaving fewer receptors available for TGF-a
binding.24,27 The high-expressing animals are somehow able
to circumvent this restriction in the availability of receptor
sites. Similar results have been reported using the regula¬
tory elements of keratin K14 to drive the expression ofTGF-a
to the epidermis of transgenic mice.3 However, for both
studies, although the transgenic phenotype is hyperplas-
tic, it does not truly mimic the psoriatic phenotype since
the transgenic model displays little inflammatory response,
as is seen in psoriatic lesions. Thus, other factors must
induce the inflammatory response in this disease and, to
mimic psoriasis more faithfully, it will be necessary to
identify these factors and assess their synergism with TGF-a
in transgenic mice.
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Interestingly, several of the HKl.TGF-a-expressing
animals developed tumors at about 10 to 14 weeks of
age. These tumors appear to be associated with a wound¬
ing stimulus such as occurs with scratching and biting.
These tumors show a squamous papilloma histotype simi¬
lar to tumors induced by the ras oncogene (Figure 3),
although the tumors on HK1.TGF-a animals are more
prone to regrssion. We are currently assessing the induc¬
tion kinetics of these papillomas and determining the con¬
tribution of overexpression of TGF-a to epidermal tumor
pathology (see below).
Another growth factor that profoundly affects skin
and has been shown to be involved in wound healing is
TGF beta (TGF-ß). In vitro studies have shown that TGF-ß
will induce proliferation of dermal fibroblasts28 but, in
contrast, will inhibit growth of epidermal keratinocytes.29
Moreover, immunohistochemical and in situ hybridiza¬
tion studies have suggested a role for TGF-ß in cutaneous
development (see references in Sellheyer et al7). To ob¬
tain more direct evidence for the involvement of TGF-ß
in skin development as well as in wound healing, we have
targeted its expression to the epidermis of transgenic mice.7
Mice expressing the HK1.TGF-ß transgene exhibited a
marked phenotype at birth (Figure 4). The skin of these
animals was very shiny and taut, resulting in rigidity and
restricting the animals' ability to move. Death usually oc¬
curred within 24 hours. A histologie examination re¬
vealed a compact orthohyperkeratosis and a reduction in
the number of hair follicles. The proliferative capacity of
the basal epidermal cells was almost completely shut down
in these animals, possibly as early as day 15 of embryo-
genesis, the time at which the Kl promotor first becomes
active. The inhibition of growth of the epidermis, while
the other tissues of the embryo continued to grow, pro¬
duced transgenic pups that resembled overinflated bal¬
loons (Figure 4). We are currently attempting to produce
animals that express the HK1.TGF-ß transgene focally,
ie, patchy rather than generalized expression, in the hope
of generating transgenic animals that survive into adult¬
hood. If we are successful, then these mice will be used
to assess the role of TGF-ß in cutaneous wound healing.
TRANSGENIC MODELS
OF SKIN CANCER
It is now well established that cancer is a multistage pro¬
cess driven by the accumulation of discrete complimen¬
tary events.30 Molecular studies strongly support the no¬
tion that these changes occur at the genetic level and in¬
volve two distinct classes of genes: transforming genes or
oncogenes31 and tumor suppressor genes or antioncogenes.52
It is envisaged that oncogenes become "activated" by a va¬
riety of mutations that alter their function in a dominant
fashion resulting in transformation. Conversely, tumor sup¬
pressor genes become inactivated or are changed, so that
they no longer exert their antitumor activity. As the fre-
quency of skin cancer in the United States approaches that
of all others combined,33 it is ofvital importance to develop
relevant in vivo model systems that closely mimic putative
failures in oncogenes or tumor suppressor genes that re¬
sult in neoplasia. Mathematical models predict that at least
seven genetic "hits" are required for epidermal cancers.34
We have attempted to characterize these discrete genetic
insults by targeting relevant oncogenes to the epidermis
and determining their contribution to the disease state.
M OST OF the data available for the mul-tistate nature of skin cancer has beengenerated by the topical application ofchemical mutagens to murine epider-
the first lesion to appear is a benign papilloma that can per¬
sist, regress, or convert to a fully malignant tumor. A mo¬
lecular analysis of these papillomas has implicated an ac¬
tivated ras oncogene as playing a role in the early stages of
skin carcinogenesis. Normal ras function involves relaying
signals to impinge on the cell surface to the cell nucleus37
and activating mutations in this oncogene are thought to
maintain the ras protein product in a permanently "on" state.
Since these signals normally pertain to cell growth and di¬
vision, a mutated ras is envisaged to maintain this signal
for mitosis regardless of the messages that are received on
the cell surface. This is supported by the observation that
an activated ras introduced into normal keratinocytes and
grafted onto the back of nude mice will induce the devel¬
opment of a benign tumor at the graft site.38 Moreover, ras
activation has been strongly implicated to play a causal role
in human skin cancer by the finding that a high incidence
of ras mutations occurs in sun-exposed carcinomas,39 pos¬
sibly generated by UV-induced pyrimidine dimers. Acti¬
vating ras mutations have also been associated with benign
self-regressing human keratoacanthomas,40 suggesting an
early role.
Thus, to investigate the role of activating ras muta¬
tions to tumor formation and to develop a model for hu¬
man skin cancer, we expressed a mutated ras in the epi¬
dermis of transgenic mice (HKl.ras).8 This expression re¬
sulted in neonates that exhibited a thickened wrinkled skin
and massive hyperplasia similar to that observed in the
HK1.TGF-a mice (Figure 2). The hyperplasia progresses
to hyperkeratosis resulting in a gross scaly and keratotic
appearance. The newborn hyperplasia and juvenile hyper¬
keratosis are consistent with a role for ras in the signaling
pathway that determines cell division and is also consis¬
tent with the proliferative basal cells of these mice becom¬
ing less responsive to inducers of differentiation. Interest¬
ingly, the phenotype did not persist and, by 4 weeks, all
the transgenic animals were indistinguishable from their
normal littermates. However, at about 10 to 12 weeks, the
transgenic animals developed tumors typical ofbenign pap¬
illomas (Figure 4). These tumors could be characterized as
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Figure 4. Top, Gross phenotypic morphologic appearance of a HK1. TGF-ß
transgenic pup (upper) and a normal littermate (lower) 1 hour after birth.
Center, Histologie appearance of transgenic skin shows a thinner epidermis
and more compact orthohyperkeratosis than control skin (bottom)(magnification x667). Reproduced from Sellheyer et al.7
either dependent or independent of a promotion stimulus
such as wounding. Only one tumor type was observed in
any individual animal. Those animals with wounding-
dependent tumors developed papillomas at the ear tag, bi¬
opsy sites, and areas prone to scratching or biting. These
mice were also remarkably sensitive to the chemical 12-
0-tetradecanoyl-phorbol-13-acetate (TPA); in essence, the
entire treated area represented a single large papilloma. In
contrast, mice with tumors independent ofa wounding stimu¬
lus developed only small sporadic tumors under the same
conditions. Regardless of the type of tumor, most regressed
and, to date, only a single tumor has progressed to ma¬
lignancy, as determined by histologie study, keratin marker
expression, and macroscopic observation, over the appar¬
ently normal lifespan of these transgenic animals. These
results suggest that other genetic "hits" are required to main¬
tain autonomous papilloma growth and, for progression
to a fully malignant tumor, consistent with the multistage
nature of skin carcinogenesis.
It should be noted that the phenotype observed in our
HK1. ras mice was not reported in a similar study5 that used
Figure 5. Top, Gross appearance of a typical HKLtos mouse demonstrates
a novel ear lesion associated with a wounding stimulus and appearing
highly keratotic. Bottom, Histologie appearance of the tumor shows
massive keratosis in this lesion but no evidence of progression to
malignancy (magnification x 167).
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the regulatory elements of the differentiation-specific kera¬
tin, K10, to target an activated ras to the epidermis. In the
study by Bailleul et al,5 ras expression was directed solely to
suprabasal keratinocytes, cells that have already differenti¬
ated and are no longer capable of mitosis, resulting only in
a hyperkeratotic phenotype without hyperplasia. Moreover,
their study was especially hampered by ras expression in the
forestomach, which produced a marked hyperkeratosis in
that organ, contributing to early death, thus preventing the
assessment of tumor progression, if any, in these animals.
SINCE the expression of ras alone was insuffi¬cient for complete carcinogenesis, we targetedother oncogenes to the epidermis to assess theirsynergism with an activated ras oncogene intransgenic animals. One of the more promi¬
nent proto-oncogenes expressed in the epidermis isJos, and
it appears to be particularly prevalent in granular layer cells
that are about to comify,41,42 suggesting a role for thefos pro¬
tein in epidermal differentiation. Moreover, earlier tissue cul¬
ture studies have shown that activated fos is able to cause
malignant conversion or activated ras-induced papillomas,
demonstrating direct cooperation between ras and fos on¬
cogenes.43,44 To explore this synergism in vivo, we targeted
a highly mutated form oífos to the epidermis of transgenic
mice using our HK1 vector (HK1.Jos).9 Transgenic animals
were indistinguishable from their normal littermates until
approximately 2 months of age when they developed a very
charactecteristic hyperplasia and hyperkeratosis of the ear
epidermis. This phenotype was accelerated bywounding and,
at 8 to 9 months of age, appeared in axilla and inguinal ar¬
eas, sites that are associated with frictional irritation. This
indicates that a second promoting event, such as wounding
or friction, is required to elicit these pathologic changes. We
believe that the appearance of these highly keratotic lesions
suggest that the activated fos transgene is interfering with
the normal role oífos in the differentiation of granular cells
to comified squames. With time, these hyperkeratotic le¬
sions developed intohighlykeratoticbenign tumors (Figure 5).
A second tumor type was also observed in these animals,
which resembled benign squamous papillomas. While these
tumors were likewise associated with a preexisting pheno¬
typic epidermis, they appeared singly at multiple sites, sug¬
gesting a more clonal origin. Regardless of the tumor his-
totype, malignant conversion was observed in only one of
these lesions occurring on an old (> 16 months) individual.
Like the ras oncogene studies, these studies have shown that
activating/os mutations are insufficient to elicit complete car¬
cinogenesis.
Having established transgenic mice with exclusive
epidermal pathologic findings that express activated fos
or ras oncogenes, we assessed the effects on epidermal
keratinocytes expressing both oncogenes. This was sim¬
ply done by mating HK1. ras and HK1.fos animals.45 The
progeny from these matings exhibited an increase in the
severity of the ras-associated phenotype of hyperplasia and
hyperkeratosis. Most notably, these mice developed tu¬
mors almost immediately with lesions visible in the axilla
and inguinal areas by 3 weeks of age. By 6 weeks, these
early lesions continue to grow aggressively but remain pe-
dunculated, and numerous new tumors appear on the in¬
tegument of these animals. At 10 to 12 weeks, the larger
tumors begin to compromise the animal, necessitating sac¬
rifice. However, these tumors, although highly aggres¬
sive, remained benign squamous papillomas with large
areas of dysplasia but without signs of malignancy of car¬
cinoma in situ. The results from these matings show that
activated ras and fos oncogenes can cooperate to poten¬
tiate the severity of the benign tumor but are still insuf¬
ficient for complete carcinogenesis suggesting the require¬
ment of other genetic hits to produce malignant conversion
of these tumors. Thus, we are currently endeavoring to
expand these matings to include mice expressing the
HK1.TGF-a transgene and mice lacking a functional p53
tumor suppressor gene. Overexpression of TGF-a has been
shown to augment the size and aggressive nature of ras-
induced papillomas,46 and recent studies have suggested
synergism between ras and TGF-a in epidermal papillo¬
mas.47 In addition, inactivating mutations of p53 have been
associated with malignant conversion of papillomas in chemi¬
cally treated mouse skin.48
SUMMARY AND FUTURE PROSPECTS
The application of transgenic technology to cutaneous re¬
search has provided multiple advances in our understand¬
ing of skin function. Reverse genetic experiments have
elucidated keratin function and contributed to our un¬
derstanding on the assembly of keratin filaments. More¬
over, these studies have prompted investigations that have
led to the discovery of the molecular basis for the domi-
nantly inherited skin diseases, EBS and EHK. We have
also exploited the expression characteristics of an HK1
genomic fragment to target exogenous gene expression
exclusively to the epidermis. In this way, we have ob¬
served the effects on the epidermis of overexpression of
growth factors such as TGF-a and TGF-ß and the onco¬
genes ras and fos. These mice exhibit profound epidermal
changes and have provided the means to identify the con¬
tribution of each of these proteins to both normal skin
function and the disease state. Moreover, these animals
are useful models of human skin diseases and will allow
us to test gene therapy techniques for the treatment of
these genetic diseases. The skin, given its accessibility and
ease of handling, is destined to become an important site
for the application of these new technologies.
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